These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 10850638)

  • 21. Underlying Role of Brushite in Pathological Mineralization of Hydroxyapatite.
    Zhang J; Wang L; Putnis CV
    J Phys Chem B; 2019 Apr; 123(13):2874-2881. PubMed ID: 30840456
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phosphates precipitating from artificial urine and fine structure of phosphate renal calculi.
    Grases F; Sohnel O; Vilacampa AI; March JG
    Clin Chim Acta; 1996 Jan; 244(1):45-67. PubMed ID: 8919201
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of inositol hexaphosphate (phytate) on calcium binding, calcium oxalate crystallization and in vitro stone growth.
    Saw NK; Chow K; Rao PN; Kavanagh JP
    J Urol; 2007 Jun; 177(6):2366-70. PubMed ID: 17509360
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potential thermodynamic and kinetic roles of phytate as an inhibitor of kidney stone formation: theoretical modelling and crystallization experiments.
    Fakier S; Rodgers A; Jackson G
    Urolithiasis; 2019 Dec; 47(6):493-502. PubMed ID: 30767040
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of two new polysaccharides on growth, agglomeration and zeta potential of calcium phosphate crystals.
    Boevé ER; Cao LC; Deng G; De Bruijn WC; Schröder FH
    J Urol; 1996 Jan; 155(1):368-73. PubMed ID: 7490888
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibitors of crystal growth of hydroxyapatite: a constant composition approach.
    Wilson JW; Werness PG; Smith LH
    J Urol; 1985 Dec; 134(6):1255-8. PubMed ID: 2997488
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Urinary lithogen risk test: usefulness in the evaluation of renal lithiasis treatment using crystallization inhibitors (citrate and phytate).
    Conte A; Pizá P; García-Raja A
    Arch Esp Urol; 1999; 52(1):94-9. PubMed ID: 10101897
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Study of the effects of different substances on the early stages of papillary stone formation.
    Grases F; Garcia-Ferragut L; Costa-Bauzá A; March JG
    Nephron; 1996; 73(4):561-8. PubMed ID: 8856252
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Crystallization conditions in urine of patients with idiopathic recurrent calcium nephrolithiasis and with hyperparathyroidism.
    Baumann JM; Lauber K; Lustenberger FX; Wacker M; Zingg EJ
    Urol Res; 1985; 13(4):169-74. PubMed ID: 4049602
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pyrophosphate does not influence calcium oxalate or calcium phosphate crystal formation in concentrated whole human urine.
    Hallson PC; Rose GA; Sulaiman S
    Urol Res; 1983; 11(4):151-4. PubMed ID: 6316611
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Urinary lithogen risk test: usefulness in the evaluation of renal lithiasis treatment using crystallization inhibitors (citrate and phytate).
    Conte A; Pizá P; García-Raja A; Grases F; Costa-Bauzá A; Prieto RM
    Arch Esp Urol; 1999 Apr; 52(3):305-10. PubMed ID: 10371752
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Uric acid as inducer of calcium oxalate crystal development.
    Grases F; Sanchis P; Isern B; Perelló J; Costa-Bauzá A
    Scand J Urol Nephrol; 2007; 41(1):26-31. PubMed ID: 17366099
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phytate Dephosphorylation Products Also Act as Potent Inhibitors of Calcium Oxalate Crystallization.
    Grases F; Costa-Bauzá A; Calvó P; Julià F; Dietrich J; Gomila RM; Martorell G; Sanchis P
    Molecules; 2022 Aug; 27(17):. PubMed ID: 36080228
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is calcium oxalate nucleation in postprandial urine of males with idiopathic recurrent calcium urolithiasis related to calcium phosphate nucleation and the intensity of stone formation? Studies allowing insight into a possible role of urinary free citrate and protein.
    Schwille PO; Schmiedl A; Manoharan M
    Clin Chem Lab Med; 2004 Mar; 42(3):283-93. PubMed ID: 15080561
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Urinary supersaturation with respect to brushite in patients suffering calcium oxalate lithiasis.
    Berland Y; Boistelle R; Olmer M
    Nephrol Dial Transplant; 1990; 5(3):179-84. PubMed ID: 2113644
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A simple technique for assessing the propensity for crystallization of calcium oxalate and brushite in urine from the increment in oxalate or calcium necessary to elicit precipitation.
    Nicar MJ; Hill K; Pak CY
    Metabolism; 1983 Sep; 32(9):906-10. PubMed ID: 6888271
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of magnesium oxide on the crystallization of calcium salts in urine in patients with recurrent nephrolithiasis.
    Fetner CD; Barilla DE; Townsend J; Pak CY
    J Urol; 1978 Oct; 120(4):399-401. PubMed ID: 702659
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nephrocalcinosis in Calcium Stone Formers Who Do Not have Systemic Disease.
    Bhojani N; Paonessa JE; Hameed TA; Worcester EM; Evan AP; Coe FL; Borofsky MS; Lingeman JE
    J Urol; 2015 Nov; 194(5):1308-12. PubMed ID: 25988516
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transformation of modified brushite to hydroxyapatite in aqueous solution: effects of potassium substitution.
    Kumar M; Xie J; Chittur K; Riley C
    Biomaterials; 1999 Aug; 20(15):1389-99. PubMed ID: 10454010
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Key Aspects of Myo-Inositol Hexaphosphate (Phytate) and Pathological Calcifications.
    Grases F; Costa-Bauza A
    Molecules; 2019 Dec; 24(24):. PubMed ID: 31817119
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.